These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38006445)
1. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database. Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445 [TBL] [Abstract][Full Text] [Related]
2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
3. Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer. Lenis AT; Ravichandran V; Brown S; Alam SM; Katims A; Truong H; Reisz PA; Vasselman S; Nweji B; Autio KA; Morris MJ; Slovin SF; Rathkopf D; Danila D; Woo S; Vargas HA; Laudone VP; Ehdaie B; Reuter V; Arcila M; Berger MF; Viale A; Scher HI; Schultz N; Gopalan A; Donoghue MTA; Ostrovnaya I; Stopsack KH; Solit DB; Abida W Clin Cancer Res; 2024 Sep; 30(17):3894-3903. PubMed ID: 38949888 [TBL] [Abstract][Full Text] [Related]
4. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y J Gastroenterol; 2023 Jun; 58(6):575-585. PubMed ID: 37029223 [TBL] [Abstract][Full Text] [Related]
5. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311 [TBL] [Abstract][Full Text] [Related]
6. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255 [TBL] [Abstract][Full Text] [Related]
7. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399 [TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091 [TBL] [Abstract][Full Text] [Related]
9. Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden. Choi J; Park KH; Kim YH; Sa JK; Sung HJ; Chen YW; Chen Z; Li C; Wen W; Zhang Q; Shu XO; Zheng W; Kim JS; Guo X Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):712-720. PubMed ID: 38393316 [TBL] [Abstract][Full Text] [Related]
10. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China. Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314 [TBL] [Abstract][Full Text] [Related]
11. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975 [TBL] [Abstract][Full Text] [Related]
12. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
13. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma]. Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256 [No Abstract] [Full Text] [Related]
14. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172 [TBL] [Abstract][Full Text] [Related]
15. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
16. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Karamitopoulou E; Andreou A; Wenning AS; Gloor B; Perren A Eur J Cancer; 2022 Jul; 169():64-73. PubMed ID: 35512587 [TBL] [Abstract][Full Text] [Related]
17. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692 [TBL] [Abstract][Full Text] [Related]
18. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914 [TBL] [Abstract][Full Text] [Related]
19. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596 [TBL] [Abstract][Full Text] [Related]
20. Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts. Li Z; Jia Y; Zhu H; Yuan H; Xing X; Xin Y; Ma T; Pang F; Zhang Y; Hu Y; Jia S; Ji J Int J Cancer; 2022 Oct; 151(8):1382-1393. PubMed ID: 35567574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]